We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Panel of Oligonucleotide Probes and Primers Ready for Influenza Researchers

By LabMedica International staff writers
Posted on 21 Apr 2010
Molecular biologists and virologists working on the influenza virus will welcome the introduction of a new panel of oligonucleotide probes and primers that may be used to resolve the genetic signatures of a variety of influenza strains.

The panel is being marketed by Biosearch Technologies (Novato, CA, USA) and is produced under license from the developer, the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) and from F. More...
Hoffmann-La Roche (Basel, Switzerland).

The reagents – probes and primers – are intended for use in qPCR (quantitative real time polymerase chain reaction) protocols. The procedure for qPCR follows the general principle of polymerase chain reaction; its key feature is that the amplified DNA is detected as the reaction progresses in real time, compared to standard PCR, where the product of the reaction is detected at its end. Two common methods for detection of products in real-time PCR are (1) nonspecific fluorescent dyes that intercalate with any double-stranded DNA, and (2) sequence-specific DNA probes consisting of oligonucleotides that are labeled with a fluorescent reporter, which permits detection only after hybridization of the probe with its complementary DNA target.

The Biosearch Influenza A Subtyping ValuPanel Reagents comprise oligonucleotides based on the following seven signature sequences: universal strain of influenza A; influenza A H1 subtype; influenza A H3 subtype; influenza A H5a subtype; influenza A H5b subtype; universal strain of influenza B, and RNase P as a positive control.

"Over the past few years, Biosearch has developed advanced manufacturing capability and quality system management, which set us apart from traditional oligonucleotide suppliers,” said Dr. Ron Cook, president and CEO of Biosearch Technologies. "We are pleased to apply our expertise to provide these important new reagents for the detection of all major strains of influenza. We expect to augment this listing as new assays become available.”

Related Links:
Biosearch Technologies
Centers for Disease Control and Prevention
F. Hoffmann-La Roche



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.